Kura Oncology, Inc.KURANASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank71
3Y CAGR+268.7%
5Y CAGR-1.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+268.7%/yr
vs -64.1%/yr prior
5Y CAGR
-1.3%/yr
Recent acceleration
Acceleration
+332.9pp
Accelerating
Percentile
P71
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
3 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 55.60% |
| 2024 | 52.49% |
| 2023 | 7.47% |
| 2022 | 1.11% |
| 2021 | 48.64% |
| 2020 | 59.30% |
| 2019 | 22.10% |
| 2018 | 66.78% |
| 2017 | 21.20% |
| 2016 | 30.80% |